The upregulation of PD-L1 is a common phenomenon in cancer patients,[24] leading to enhanced T-cell immunodeficiency and high immune suppression.[25] PD-L1 could possibly be a consequence of proinflammatory cytokine produced by tumor-infiltrating lymphocytes (TILs). The gene discussed is CD274; the disease is cancer.